Therefore, all these results suggest that, in the early stages of NASH, BPF99 revers the lipid-induced redox-imbalance in mouse liver, probably through the inhibition of ROS/JNK/p38-MAPK pathway, responsible for the overproduction of inflammatory and fibrotic markers. This evidence concerns the gene MAPK14 and metabolic dysfunction-associated steatohepatitis.